About Farnesyl pyrophosphate synthase
Farnesyl pyrophosphate synthase (FDPS) is a protein
from Homo sapiens identified by UniProt accession
P14324, 419 residues long.
MolForge cross-references it against 0 known binders and
212 disease associations.
Target properties
| Protein name | Farnesyl pyrophosphate synthase |
| UniProt accession | P14324 |
| Gene | FDPS |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (9)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (212)
Diseases linked to this target (Open Targets).
- disseminated superficial actinic porokeratosis · score 0.62
- osteoporosis · score 0.61
- postmenopausal osteoporosis · score 0.60
- multiple myeloma · score 0.60
- osteitis deformans · score 0.60
- prostate carcinoma · score 0.60
- metastasis · score 0.60
- prostate cancer · score 0.60
- breast cancer · score 0.60
- Osteopenia · score 0.57
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P14324-F1 | alphafold | PREDICTED | 85.38 | — |
Amino-acid sequence (419 residues)
MPLSRWLRSV GVFLLPAPYW APRERWLGSL RRPSLVHGYP VLAWHSARCW CQAWTEEPRA LCSSLRMNGD QNSDVYAQEK QDFVQHFSQI VRVLTEDEMG HPEIGDAIAR LKEVLEYNAI GGKYNRGLTV VVAFRELVEP RKQDADSLQR AWTVGWCVEL LQAFFLVADD IMDSSLTRRG QICWYQKPGV GLDAINDANL LEACIYRLLK LYCREQPYYL NLIELFLQSS YQTEIGQTLD LLTAPQGNVD LVRFTEKRYK SIVKYKTAFY SFYLPIAAAM YMAGIDGEKE HANAKKILLE MGEFFQIQDD YLDLFGDPSV TGKIGTDIQD NKCSWLVVQC LQRATPEQYQ ILKENYGQKE AEKVARVKAL YEELDLPAVF LQYEEDSYSH IMALIEQYAA PLPPAVFLGL ARKIYKRRK
Explore Farnesyl pyrophosphate synthase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets